“…Twenty-nine studies [138][139][140]143,145,148,150,152,[154][155][156][158][159][160][165][166][167][168]170,173,174,[178][179][180][181][182][183]186,188 provided incidence of TB among kidney-only recipients, while 13 studies 141,142,146,149,157,161,164,171,172,184,185,187,189 Rejection prior to TB occurred in 184 of 531 (34.65%) cases. The use of CD4-depleting agents such as muromonab (OKT-3) or alemtuzumab (anti-CD52) was detailed in 13 of 38 (34.21%) case reports, 9,13,21,25,39,59,74,…”